TBF Genie Tissulaire — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

TBF Génie Tissulaire is a well-established, private French leader in the processing and distribution of human tissue allografts. Operating as a subsidiary of Groupe Lépine, it has a nearly 30-year legacy (dating to the group's 1993 founding) providing surgeons with a portfolio of bone grafts, demineralized bone matrix (DBM), amniotic membranes, and nerve conduits. The company is fully commercial, generating revenue from its banked tissues, and is distinguished by its regulatory authorization, extensive clinical history with over 200,000 grafts implanted, and a strong focus on safety, innovation, and ethical collaboration with healthcare professionals.

OrthopedicsDentistryOphthalmologyPeripheral Nerve Repair

Technology Platform

Integrated human tissue bank platform encompassing ethical donor sourcing, proprietary processing (including viral inactivation and lyophilization), and formulation of allografts into various formats (powders, fibers, membranes, conduits) for orthopedic, dental, ophthalmological, and nerve repair applications.

Opportunities

Securing reimbursement for core bone graft products in France is a major commercial catalyst that should drive significant market penetration and revenue growth.

Expanding the application of its trusted tissue processing platform into adjacent high-value surgical niches, such as peripheral nerve repair and advanced ophthalmology, presents opportunities for margin expansion and market leadership in specialized segments.

Risk Factors

The business is entirely dependent on a sensitive and regulated supply chain of human tissue donations, which could be disrupted.

Maintaining its critical authorization from the ANSM is paramount, as any failure in safety or quality control could be existential.

The company faces competition from other tissue banks, synthetic biomaterials, and advanced regenerative therapies.

Competitive Landscape

TBF competes in the human allograft market against other tissue banks and processors, both in France and internationally. It also faces competition from synthetic bone graft substitutes, xenografts, and emerging cell-based therapies. Its key competitive advantages are its first-mover status as an ANSM-authorized French bank, a long clinical track record, a broad portfolio across multiple surgical disciplines, and proprietary processing technologies emphasizing safety and surgeon convenience.

More companies in Regenerative Medicine →More companies in France →